CA2659442C - Cinnamomi and poria composition and uses thereof - Google Patents

Cinnamomi and poria composition and uses thereof Download PDF

Info

Publication number
CA2659442C
CA2659442C CA2659442A CA2659442A CA2659442C CA 2659442 C CA2659442 C CA 2659442C CA 2659442 A CA2659442 A CA 2659442A CA 2659442 A CA2659442 A CA 2659442A CA 2659442 C CA2659442 C CA 2659442C
Authority
CA
Canada
Prior art keywords
extract
give
granules
poria
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2659442A
Other languages
French (fr)
Other versions
CA2659442A1 (en
Inventor
Wei Xiao
Xiang Ling Dai
Ya Ling
Zhen Zhong Wang
Yu An Bi
Zheng Kuan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Kanion Pharmaceutical Co Ltd
Original Assignee
Jiangsu Kanion Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39644933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2659442(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jiangsu Kanion Pharmaceutical Co Ltd filed Critical Jiangsu Kanion Pharmaceutical Co Ltd
Publication of CA2659442A1 publication Critical patent/CA2659442A1/en
Application granted granted Critical
Publication of CA2659442C publication Critical patent/CA2659442C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/54Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/65Paeoniaceae (Peony family), e.g. Chinese peony
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Abstract

A method of preparing and analyzing a Chinese herbal composition comprising Ramulus cinnamomi and Poria cocos is provided, wherein the resulted composition is defined by a 12-peak fingerprint obtained from an improved chromatographic method for quality control. Compared to traditional methods, the claimed method better preserves the effective ingredients of Cinnamomi and Poria. The resulted composition is proven effective in treating hysteromyoma. Various uses of such composition are also provided.

Description

1.1()2MINAM410 PCT/182.4M70448.3 CINNAMOUZ AND PORIA COMPOSITION AND USES THEREOF
[0001] This appication claims priority of U.S. provisional i-.)p1ication O. 80/829,945, filed October 18; 2036, FIELD OF THE INVENTION
[0002] h prseiiti rnventioh is related to the mak71.nq afld using of a comvcsiLion cojlprising Chine5e herbal medicines Ra4/01).5 vimiamomi and Por.ia covos ma,!re: (-417.11 díìd Fuling).
BACKGROUND OF THE INVENTION
[0003] Traditional Chinee medicine emplcvs, herbal formulations to treat bodily .ailments. In some cases, single herbs or herb derivatives are used. More commonly, however, 2.0 "formulas", o7: specific combinations of several particular herbs, are administered. The following five herbal materials have been used in Traditional Chinese medicine for more than 2000 years. They have been recorded in many historical Chinese and are qjõted in many articles publ:4ted in COhte=nrarV BCLentific journals.
COMMON NAME LATIN NAME CHINESE NAME
Cassia 7wig RaMviuS cinOamomi Cuizbt Indian Bread Pcria coops Furtng Peach Seed Semen porsiGae Tao Pen Whitc Pocny Root Radx paccniac alZ-)a Bai Shao Tree Peony Bark Cortex mcutan Mu Dan Pi,
[0004] Cassia 2wio is the drieh yming stem of Cinnamcmum cassia Presi (Fam. Lauraceae). The .;:lanL is collected in spring or sdmmex. ft is dried in the: sun after collection and removal 7:f Its leaves can also be chopped in7..p slides. The aledioinal preparation has cylindrical body, =multi-bmnched, 50,-75 cm in .i.entb, with a thick en0 of 0.3-1 cm in cii,Ecmter. IL

is brown or reddish-brown on the surface, with longitudinal lines, fine wrinkles, dotted with leaf, branch or bud scars.
Hard and fragile, it is easily broken. For slices, it is 2-4 mm thick, cut surface showing reddish-brown in the bark area, yellowish-white to pale yellowish-brown in the wood part.
It has a characteristic aromatic odor, and is tasted sweet or slightly pungent (especially in the bark).
The medicinal preparation is the clean scraps of Cinnamomi without visible impurities. The important ingredients of Cinnamomi is cinnamaldehyde and cinamic acid.
[0005]
Indian Bread is the dried sclerotium of the fungus, Poria cocos (Fam. Polyporaceae).
The plant is collected from July to September. After collection, it was piled up and spread about for air-drying repeatedly until wrinkles appears on the surface and its inner moisture evaporated.
The whole dried sclerotium is known as "Fulingge".
If the fresh sclerotium is peeled before drying, the separated parts are called "Fulingpi"
(peel) and "Fulingkuai" (flesh).
[0006]
The outer skin is thin and rough, brown to blackish brown, conspicuously shrivelled and striated.
The texture is hard and compact.
It is odourless, tastes weak and becomes sticky when chewed.
The medicinal preparation is the clean scraps of Poria without visible Impurities.
Its important active ingredients are Pachman and Pachymic acid.
[0007]
A number of United States Patents and literatures have taught methods of composing curative compositions from herbs like Cinnamomi, Poria etc. A number of investigators from China have also reported on animal or clinical research using certain Cinnamomi and Poria composition.
[0008]
In U.S. Patent No. 6,093,403, a formula consists of Poria extract up to 20% in weight is been used to treat or prevent disorders in sugar balance, diabetes, and blood circulation diseases such as Angina Pectoris.
[0009]
Poria cocos wolf is being use for treating cardio-, cerebro-vascular diseases, Alzheimer's and depression.
A
composition containing Poria cocos wolf up to 20% of its weight has been disclosed in U.S. Patent No. 5,589,182.
[0010]
He et al. has published an article in 1994 on clinical study of a Cinnamomi and Poria composition in 100 cases of gynecopathies: dysfunctional uterine bleeding caused by irregular shedding of uterine endometrim, chronic pelvic inflammations, dysmenorrhea and small intramural hysteromyoma.
In comparison with 50 cases of patients that were treated with another medicinal preparation (Bolus of Cinnamomi and Poria, BCP), observations based on multiple complaining symptoms and physical signs showed no significant difference between the two groups.
[0011]
Shi et al. reported in 2000 the therapeutic effects of a Cinnamomi and Poria composition in 60 patients with hysteromyoma.
Patients accepted physical gynecology examination, ultrasonic examination and hematochrome test. The Shi's study reported an effective rate of 91.7%, and among which, 10% of the cases was of significant improvement.
The effectiveness of treatment was defined as "significant improvement" if the tumor was reduced 3-5 cm and enlarged menstrual flow was reduced 50% or more; or "improvement" if the tumor was reduced 2-3 cm and menstrual flow was reduced 25% or more.
[0012]
The present invention provides a herbal composition comprising Cinnamomi and Poria that would be effective in relieving symptoms of a number of diseases such as those discussed above.
In contrast to the more traditional practice in Chinese medicine, the present invention is produced by updated technologies which could better preserve the effective ingredients of Cinnamomi and Poria.
[0013] Throughout this application, various puIclications are referenced and full citations fcr these publications may be found in the references at the end ot the specifications receding the claims.
[0014] The present invention provides a composition comprising Chinese herbal medicines Ramulus cinnamomi and Poria cocos (Chinese name: Gdizhi and Fuling). In one embodiment, the herbal composition is formulated into capsule
[0015] The herbal composition of the present ilvention is defined by a HPLC tfngerprint that displays 12 peaks.
Extracting the herbal composition with methanol and analyzed against paeoniflorin as a standard, the 12 peaks have the following characteristic:
Common Relative Retention Time Relative Peak Area Range Peak No. Range 1 0. 209-0. 314 0. 25-0. 89 2 0. 456-0. 683 3 0. 733 -O. 999 4 0. 871 -1. 306 5 0. 921-1. 382 6 0. 968 -1. 451 7 1. 009 -1. 514 8 1. 058-1. 587 0. 69-1. 50 9 1. 152-1. 728 0. 30-0. 85 10 1. 690-2. 536 11 1. 771-2. Ã57 12 1. 943-2. 915 1. 56-3. 06
[0016]
In one embodiment, the present invention provides a herbal composition comprising Ramulus cinnamomi and Poria cocos, wherein the composition produces 12 peaks when subjected to a method comprising the steps of: a) extracting the composition with an appropriate organic solvent; and h) performing chromatographic analysis.
The relative retention time ranges for peaks 1-12 as compared to paeoniflorin are 0.209-0.314, 0.456-0.683, 0.733-0.999, 0.871-1.306, 0.921-1.382, 0.968-1.451, 1.009-1.514, 1.058-1.587, 1.152-1.728, 1.69-2.536, 1.771-2.657, and 1.943-2.915 respectively.
[0017]
In another embodiment, the present herbal composition further comprises paeoniflorin and paeonol.
Preferably, there are 1.26-1.90% paeoniflorin and 0.71-1.07% paeonol.
[0018]
In another embodiment, the present invention provides a composition produced by a method comprising the steps of: (a) preparing Poria powder; (b) preparing extracts of Cortex moutan;
(c) preparing extracts of Ramulus cinnamomi; (d) preparing extracts of Radix paeoniae alba, Semen persicae and Poria; (e) combining the extracts obtained from steps (b)-(d); (f) mixing the Poria powder with the extracts obtained from step (e), and generating fine powders; and (g) mixing the fine powders with inclusion substances comprising extracts of Cortex moutan and Ramulus cinnamomi.
[0019]
The present invention also provides a method of producing a composition comprising Ramulus cinnamomi and Poria cocos, the method comprises the steps of: (a) preparing Poria powder; (b) preparing extracts of Cortex moutan; (c) preparing extracts of Ramulus cinnamomi; (d) preparing extracts of Radix paeoniae alba, Semen persicae and Poria; (e) combining the extracts obtained from steps (b)-(d); (f) mixing the Poria powder with the extracts obtained from step (e), and generating fine powders; and (g) mixing the fine powders with inclusion substances comprising extracts of Cortex moutan and Ramulus cinnamomi. .

M() 2000M90410 ITTas2m7m4.013
[0020] The present invention also provides a pharmaceltical composition compr sing a pharmaceutically aoeptable carrier and the herbaLcomposition described herein.
[0021] :lin present i::vtlnLion also pfovides ues of the ..00mpbsition described herein irr the marl.lfature of medicament tor treating a li:aease or diaorder selected from the gro4 =jonaistng of pri,rr:y dystenOrtheel, .0ndary .dysmenOrtheal, dysfunctional uterine bleeding, chronic pelvic inflammatibns, and small intraural hysterOzyw:ia DETAILED DESCRIPTION OF THE FIGURES
[0022] Figure 1 shes Lhe HPLC fdngerprint of a cinramomi Poria capsUle composition as described. herein..
DETAILED DESCRIPTION OF THE INVENTION
[0023] The present invention provides a composition coMpriSing Chinese herbal medicines Guizhi and Fuling (Romulus cinna=mi and Porio cams). In une eMbodiment, the herbal composition can be formulated into capsule
[0024] In one_ embociimen:, the bresent inveotion provides a herbal composition comprising Ramulus cinnamcmi and Poria cocos, whereic the herbal compositior. is qefil-led 1:v e12.--pek,5 117igue 1) oba4ne by a 4inger-orintimg methcc.' !:.(imori_y_ing the Fiteps ni OXtraOtitig the (Ompo5ition With ail appropml.ate organic aolvent, and performing chromatoqraphic analysis. In one em?:oc3Lment, chrcmatcgraphib analysis is tig1-1 performance liquid ehroMatograpny (HPLC). In gereral, the preent herbal tompositien is ex:raCted with tbe orrjcnic solvent methano., and then subjected to HE'LC with_ a paeoniflorin standaId accorchLng :o orocedures weii-k=wn in the art.
[0025]
The relative peak area ranges for peaks 1, 8, 9, and 12 as compared to paeoniflorin are 0.25-0.89, 0.69-1.5, 0.3-0.85, and 1.56-3.06 respectively.
[0026] The relative retention time ranges for peaks 1-12 as compared to paeoniflorin are 0.209-0.314, 0.456-0.683, 0.733-0.999, 0.871-1.306, 0.921-1.382, 0.968-1.451, 1.009-1.514, 1.058-1.587, 1.152-1.728, 1.69-2.536, 1.771-2.657, and 1.943-2.915 respectively.
[0027]
The herbal composition of the present invention further comprises paeoniflorin and paeonol.
In one embodiment, there are 1.26-1.90% paeoniflorin and 0.71-1.07% paeonol.
[0028]
The present invention also provides a pharmaceutical composition comprising the herbal composition described herein and a pharmaceutically acceptable carrier.
In general, the herbal composition can be formulated into a pill, capsule, tablet, suspension, or syrup according to standard procedures.
[0029]
Pharmaceutical compositions for use in accordance with the present invention may include a pharmaceutically acceptable excipient or carrier.
As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation.
Representative examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition according to the uses of the herbal composition.
[0030]
The present invention also provides a method of treating a subject having a disease or disorder, comprising the step of administering to the subject an effective amount of the herbal composition disclosed herein.
The "effective amount" of an agent or composition refers to the amount necessary to elicit a desired biological response.
The effective amount of the active components of an herb or herbal remedy is the amount necessary to decrease a particular sign and/or symptom. One of ordinary skill in the art could readily determine an effective amount of the present herbal composition through conventional methods and techniques.
[0031] The herbal composition of the present invention can be used to treat a variety of disease or disorder.
A number of applications have been discussed in U.S. Patent 7,052,700.
For example, the Cinnamomi & Poria capsule can be used to treat primary or secondary dysmenorrhea, dysfunctional uterine bleeding caused by irreglar shedding of endometrim, chronic pelvic inflammations with inflammatory lower abdomen masses or small intramural hysteromyoma, and many other common pelvic disorders.
Further pharmacological studies, pre-clinical as well as clinical studies using the herbal composition of the present invention can be carried out as described in U.S. Patent 7,052,700.
[0032]
Preferably, the inventive pharmaceutical compositions of the present invention can be administered orally. In another embodiment of the invention, pharmaceutical compositions may be delivered to mucous membranes, for example, by inhalation or injection.
In general, the present inventive pharmaceutical compositions can be administered to numans and/or othex7 animals crally, rectally, parent=allv, irtfacisternally, intravaginally, triltraperLtoneallv, topically (as by powders, :-;lnitments, or drops), sucally, or as an orai or nasal spray,
[0033] Ihe invention being generally described, will be mere re:adtAy undert3tood by reference to t;:ac, following examPles which are included Merely for purpeses of illustration of certain aspects and embodiments of the present inventicn, and are not intended Lr limit the inveutioo.

Cinnamomi & Poria capsule
[0034] lhe present example provides a hercal composition ziompfinq Cininmcmi fcria in capsule form (cinnall-omi & Poria capsuiel..
The CiPramcmi Poria oApsule m-wiLains yellowish brown glanule which Uauted alighL1y ba.tex.
In ere embodiment, each capsule containing 0.31 ç of the :-.ranuLe san be stored for 24 months at room Lemperatuxe.
[0035] In one embbdimen;, the Cinnammi ane Folla capules can be produced by a process described below:
Step 1: Weigh (50%-90% of the formulation quantity) Poria Step 2: Grind the Poria into fine powder, and paas through a 100-meah sieve, Step 3! Sterilize the Poria powder by microwave. This is; designated as Poria Powder.
Step 4: Weigh Cortex mouton.
Step 5: 'Extract Cortex moutan by steam distillation.
Step 6: Collect thc liquid distillate. The Liquid Distillate is refrigerated, filtere4 and 25 cool dried to achieve: a extract.The dried extract LS
designated as Paconol.
Step 7: Save the extracted raw materials (Solid Residue 0.
Step 8: Extract Solid Residue 1 with 80-95% ethanol twice (3-5 Ernes volume for the first time and 2-4 times for the second) Boil for hours each time.
Step 9; Combine the ethanol extracts. This is Extract 1.
Step 10: Extract the solid residue with water twice (5-7 times volume for the first time aild 3-5 timcs for the second). Boil :for 1 --3 hours each time.
Step 11: Combine the aqueous extracts. This is Extract 11.

Step 12: Weigh Ramulus cinnamomi.
Step 13: Extract the volatile oil by steam distillation. Collect the yield of the volatile oil Step 14: Save the extracted raw materials (Solid Residue II).
Step 15: Extract Solid Residue II with 80-95% ethanol twice (3-5 times volume for the first time and 2-4 times for the second). Boil for 1-3 hours each time.
Step 16: Combine the ethanol extracts. This is Extract III.
Step 17: Extract the solid residue with water twice (5-7 times volume for the first time and 3--5 times for the second). Boil for 1-3 hours each time.
Step 18: Combine the aqueous extracts. This is Extract IV.
Step 19: Weigh Radix paeoniae alba, Semen persicae, and Poria (10%-50% of the 1 5 formulation quantity) .
Step 20: Add 3-5 times of 80-95% ethanol and leave at room temperature for 20-40 minutes and then boil for 1-3hours.
Step 21: Extract the solid again with 2--4 times of ethanol, and boil for 1-3 hours.
Step 22: Combine the ethanol extracts. This is Extract V.
2 0 Step 23: Extract the solid residue with water twice (5-7 times volume for the first time and3-5 times for the second). Boil for 1-3 hours each time.
Step 24: Combine the aqueous extracts. This is Extract VI.
Step 25: Combine Extract I (Step 9), III (Step 16) and V (Step 22).
Concentrate under 2 5 vacuum till no ethanol smell. This is Liquid A.
Step 26: Combine Extract II (Step 11), IV (Step 18) and VI (Step 24).
Concentrate under vacuum. This is Liquid B.
Step 27: Combine Liquid A and B. Concentrate under vacuum till the relative density equal to 1.15-1.35(60-90 C). The concentrated liquid extract is designated 3 0 as Semisolid Extract.
Step 28: Weigh I3-cyclodextrin and add into 2-3 times of water. Heat the 13-cyclodextrin solution to 50-70 C.
Step 29: Dissolve the total paeonol extract from Step 6 into 4-6 times of 80-95%
3 5 ethanol.
Step 30: Add the paeonol solution into the 0-cyclodextrin solution.
Step 31: Grind for 10-30 minutes.
Step 32: Then place into refrigerator for 12¨'36 hours.
Step 33: Filter under vacuum.
4 0 Step 34: Dry at 40-60 C. The resulted white powder is Inclusion Substance I.
Step 35: Weigh 13-cyclodextrin and add into 4-6 times of 10-30 % ethanol solution.
Add the all volatile oil from Step 13 into the I3-cyclodextrin solutionunder continuous stirring 4 5 Step 36: Keep grind for 20-40 minutes.
Step 37: Then place into refrigerator for 12-36 hours.
Step 38: Filter under vacuum.
Step 39: Dry at 40-60 C. The resulted white powder is Inclusion Substance II.
5 0 Step 40: Mix the Poria Powder with all the Semisolid Extract.
Step 41: Dry the mixture at 70-100 C, and grind into fine powders Step 42: Mix Fine Powder I with Inclusion Substances I and Inclusion Substances II.

Step 43: Add 50-80% ethanol solution to make a dough-like mass.
Step 44: Pass the wet material through a 16-24mesh sieve to obtain the granules.
Step 45: Dry the granules at 40-60 C.
Step 46: Pass the dried granules through the sieve again.
Step 47: Mix the dried granules well. This is Final Granules.
Technical Requirements
[0036]
(1) The Poria fine powder needs to be screened by 100 meshes of screen (inner diameter 150 6.6 lam.)
[0037]
(2) The concentration of crude paeonol should be no less than 90%.
[0038]
(3) Concentration must be performed under vacuumed conditions.
[0039]
(4) The volatile matter is tested for the presence of cinnamaldehyde.
[0040] (5) Material mass balance should be 5%.
Quality Control
[0041]
Creamed extractive: the creamed extractive is dark brown in color.
Its relative density should be 1.15-1.35 (60--70 C), and the content of paeoniflorin should be 1.36-2.04%
[0042]
Soft powder after mixing of Poria cocos: yellowish brown in color with a slightly bitter taste. The microbe limit:
number of bacteria can not exceed 5000 entries/g; fungus can not exceed 100 entries/g; living acarid, acarid egg or coliform should not be detected.
Content of paeoniflorin:
(1.23-0.87%).(1.23-1.87%)
[0043]
Final granules: yellowish brown with no more than 6.0%
water content.
[0044]
Capsules: clean, not sticky or mutilated in shape.
Differences in content should be no more than 10% (0.31 g/capsule).
Dissolving time is within 30 minutes. Water content should be no more than 7.0%. Content of paeoniflorin is at 1.26-1.90% and paeonol 0.71-1.07%.

Fingerprinting of Cinnamomi & Poria Capsule
[0045]
The test was carried out according to the HPLC method (Chinese Pharmacopoeia 2000 Ed, Vol. One, Appendix VI D) and the requirements for fingerprints.
HPLC Conditions and System Suitability
[0046]
Agilent 1100 Liquid Chromatograph; Alltima C18 5pm, 250mm X 4.6mm column.
Mobile Phase A contains 0.1% phosphoric acid and 5% acetonitrile aqueous solution; Mobiel Phase B
contains 0.1% phosphoric acid and 50% acetonitrile aqueous solution.
Flow rate: lml/min; detection wavelength: 230nm.
Based on the peak of paeoniflorin, the number of theoretical plates of the column should be no less than 6000. The gradient elution program runs as follows:
Time (min) A% B%

Preparation of Reference Solution
[0047] Weigh accurately certain amount of paeoniflorin standard reference, and then add suitable amount of methanol to make a solution of 50 g/m1.
Sample Preparation
[0048]
Take the content of the samples for Weight Variation Test, mix thoroughly, and grind into fine powder.
Weigh accurately about 0.25 g of the mixture and add 25 ml of 50%
methanol.
Sonicate the mixture for 30 min, and then filter.
Discard the first part of the filtrate.
Collect the rest filtrate as the test solution.

Assay
[0049]
Inject 101 of each the reference solution and the test solution into the HPLC system, and run the procedure.
Results
[0050]
As shown in Figure 1 and Table 1, 13 peaks (No. 1-12 and standard, S) were detected, and their relative retention time ranges were specified.
In addition, Peaks 1, 8, 9 and 12 were specified for the range of relative peak area (Table 1).
Such specifications were based on the combined analysis on HPLC
from many batches of Cinnamomi & Poria composition.
[0051]
According to the results presented herein, the HPLC
chromatogram of any batch of Cinnamomi & Poria composition should have the 13 characteristic peaks. The relative retention time of the 13 peaks and the relative peak area of Peaks 1, 8, 9 and 12 should be in the specified range. Through such control, the reproducibility and internal quality of Cinnamomi & Poria composition can be controlled and ensured.
HPLC data from ten different batches of Cinnamomi & Poria capsules have been confirmed to display the fingerprint profile presented herein.

Common Peaks and Their Limits in HPLC Fingerprint Common Relative Retention Time Relative Peak Area Range Peak No. Rang, 1 O. 209¨'0. 314 O. 25¨'0. 89 2 O. 456----'O. 683 3 O. 733-0. 999 4 O. 871 ¨1. 306 5 O. 921-1. 382 6 O. 968 ¨1. 451 7 1. 009'--'l. 514 8 1. 058 ¨1. 587 O. 69-1. 50 9 1. 152----'l. 728 O. 30-0. 85 10 1. 690----'2. 536 11 1. 771-2. 657 12 1. 943----'2. 915 1. 56-3. 06
[0052]
The fingerprint profile presented herein is different from the ones shown in U.S. Patent 7,052,700.
In the '700 patent, the aqueous samples for HPLC were prepared by water reflux extraction. The contents of 3 Cinnamomi & Poria capsules were mixed with 200 ml distilled water for heat reflux for 30 min (start timing at boiling).
The solution was cooled down, centrifuged for 10 min, and filtered with a 0.45 pm filtration membrane. The first part of the filtrate was discarded and the rest of the filtrate was taken as the test solution.
Consequently, the '700 patent presents four chromatograms, i.e.
one for water-soluble components, two for lipid-soluble components (of different chromatographic conditions and detection wavelengths), and one for gas Chromatography.
The first three chromatograms exhibit poor reproducibility and have some peaks overlapping with each other.
[0053]
In the instant invention, this processing method has been changed to use 50% methanol to extract the sample.
The content of the samples for Weight Variation Test was mixed thoroughly and grinded into fine powder.
Twenty five ml of methanol was added to 0.25 g of the mixture, which was then sonicated for 30 min and then filtered. The first part of the filtrate was discarded, and the rest of the filtrate was collected as the test solution.
It was found that extraction with 50% methanol resulted in more peaks, revealing not only more components of the Cinnamomi & Poria capsules, but also shows lipid-soluble and volatile components in the product.
Therefore, the current method produces only one chromatogram, which can be used in combination with other quality control procedures to control the quality of the Cinnamomi & Poria capsules.
[0054]
Hence, the difference between these two methods is that the former method of water reflux extraction extracted components that were mainly water-soluble, and the major peaks in the chromatogram were the water-soluble compounds in the product. In contrast, the method of the instant invention uses 50% methanol as the extraction solvent to extract more water-soluble components, lipid-soluble components as well as the volatile compound paeonol, and these compounds can be presented in one chromatogram that shows a higher paeonol peak based on equal sample amount.

Specificity, Reproducibility, and Stability of Cinnamomi & Poria Capsule Fingerprinting
[0055]
The evaluation parameters for the fingerprints of Traditional Chinese medicines are usually the ratios of the retention time and area of the characteristic peaks to those of the references.
The relative retention time and peak area of each peak are used for the characterization of the fingerprint.
In standard fingerprinting, the relative retention time and relative peak area of the feature peaks are specified.
[0056]
Such evaluation parameters can eliminate variations caused by differences in instruments, columns, mobile phase and environment that can change the retention time and peak area.
Therefore, these parameters can be used objectively and comprehensively to represent the actual conditions of the constituents in and the internal quality of the product.
Specificity:
[0057]
The fingerprint characteristics presented herein are unique to the Cinnamomi & Poria Capsule of the present invention.
The characteristic peaks of the fingerprint reveal constituents of every batch of Cinnamomi & Poria Capsule processed according to the disclosed manufacturing procedure.
Reproducibility:
[0058]
The current fingerprint standard was derived from optimization of assay conditions and data collected from many batches.
Results from repeated assays of the same batch, as well as data from ten different batches (Tables 2-3) show that the current method can accurately fingerprint Cinnamomi & Poria Capsule with good reproducibility.
The results also show that the constituents' contents are similar in different batches, the relative retention time and peak area of all the characteristic peaks being in the specified range.
Stability:
[0059]
The fingerprints of consecutive three batches have been studied from 0 to 12 months. The results show that there is no obvious change of the characteristic peaks in 12 months, demonstrating the stability of the quality of the product as well as the fingerprint assay method (Tables 4-6).

Finger Print Data From Five Batches Specifications from Batch No.
the Standard Chromatogram Peak No. Relative Relative 051201 051202 060101 060102 060301 Retention Peak Time Area RRT RPA RRT RPA RRT RPA RRT RPA RRT RPA
(RRT) (RPA) 0.209- 0.25-1 0.304 0.555 0.304 0.521 0.304 0.478 0.312 0.850 0.313 0.625 0.314 0.89 0.456-2 0.620 0.621 0.620 0.634 0.635 0.683 0.733-3 0.929 0.929 0.929 0.931 0.931 0.999 0.871-4 1.066 1.066 1.066 1.062 1.062 1.306 0.921-1.115 1.116 1.115 1.106 1.106 1.382 0.968-6 1.155 1.155 1.155 1.144 1.143 1.451 1.009-7 1.234 1.234 1.234 1.227 1.226 1.514 1.058- 0.69-8 1.286 1.030 1.287 0.917 1.286 1.061 1.274 0.888 1.272 0.915 1.587 1.50 1.152- 0.30-9 1.368 0.581 1.368 0.548 1.368 0.421 1.355 0.744 1.354 0.679 1.728 0.85 1.690-1.954 1.957 1.954 1.933 1.928 2.536 1.771-11 2.038 2.040 2.038 2.011 2.009 2.657 1.943- 1.56-12 2.222 1.998 2.224 1.888 2.222 2.473 2.189 2.698 2.186 1.825 2.915 3.06 Finger Print Data From Five Other Batches Specifications from Batch No.
the Standard Chromatogram Peak No. Relative Relative 060302 060401 060402 060501 060502 Retention Peak Time Area RRT RPA RRT RPA RRT RPA RRT RPA RRT RPA
(RRT) (RPA) 0.209- 0.25-1 0.291 0.488 0.291 0.485 0.291 0.607 0.313 0.556 0.313 0.662 0.314 0.89 0.456-2 0.612 0.612 0.611 0.635 0.635 0.683 0.733-3 0.926 0.926 0.926 0.931 0.931 0.999 0.871-4 1.067 1.067 1.066 1.062 1.062 1.306 0.921-1.114 1.114 1.113 1.106 1.106 1.382 0.968-6 1.154 1.153 1.153 1.143 1.143 1.451 1.009 -7 1.242 1.242 1.242 1.226 1.226 1.514 1.058- 0.69-8 1.292 0.899 1.292 0.901 1.292 0.924 1.272 0.841 1.272 0.828 1.587 1.50 1.152- 0.30-9 1.380 0.631 1.380 0.636 1.380 0.658 1.355 0.624 1.355 0.806 1.728 0.85 1.690-1.995 1.995 1.996 1.929 1.930 2.536 1.771-11 2.076 2.075 2.076 2.008 2.010 2.657 1.943- 1.56-12 2.266 2.643 2.265 2.627 2.266 2.344 2.187 1.803 2.188 2.870 2.915 3.06 Stability Data Batch No. 050301 Peak 0 Month 3 Month 6 Month 9 Month 12 Month No.
RRT RPA RRT RPA RRT RPA RRT RPA RRT RPA
1 0.270 0.630 0.252 0.632 0.304 0.639 0.274 0.636 0.267 0.637 2 0.599 0.553 0.622 0.607 0.597 3 0.925 0.912 0.927 0.921 0.921 4 1.061 1.086 1.066 1.054 1.057 1.096 1.139 1.115 1.088 1.091 6 1.135 1.187 1.156 1.121 1.128 7 1.195 1.293 1.237 1.196 1.194 g 1.276 0.803 1.349 0.805 1.286 0.810 1.261 0.808 1.272 0.811 9 1.375 0.645 1.453 0.648 1.368 0.641 1.360 0.649 1.371 0.652 2.014 2.094 1.957 1.997 2.024 11 2.076 2.205 2.045 2.029 2.065 12 2.270 2.021 2.416 2.028 2.222 2.022 2.223 2.029 2.262 2.026 Stability Data Batch No. 050302 Peak 0 Month 3 Month 6 Month 9 Month 12 Month No.
RRT RPA RRT RPA RRT RPA RRT RPA RRT RPA
1 0.273 0.579 0.260 0.577 0.304 0.572 0.274 0.571 0.267 0.570 2 0.600 0.562 0.621 0.606 0.597 3 0.925 0.914 0.929 0.921 0.921 4 1.062 1.090 1.066 1.054 1.057 5 1.096 1.130 1.116 1.086 1.091 6 1.134 1.176 1.155 1.121 1.129 7 1.195 1.247 1.234 1.192 1.196 8 1.275 0.796 1.334 0.803 1.287 0.806 1.261 0.795 1.272 0.801 9 1.375 0.539 1.458 0.542 1.368 0.543 1.360 0.536 1.371 0.545 10 2.014 2.144 1.957 1.996 2.029 11 2.076 2.255 2.040 2.029 2.065 12 2.270 1.915 2.476 1.923 2.224 1.925 2.222 1.919 2.264 1.920 Stability Data Batch No. 050303 Peak No. 0 Month 3 Month 6 Month 9 Month 12 Month RRT RPA RRT RPA RRT RPA RRT RPA RRT RPA
1 0.273 0.692 0.260 0.692 0.304 0.698 0.274 0.696 0.267 0.694 2 0.601 0.562 0.622 0.606 0.597 3 0.925 0.915 0.929 0.921 0.921 4 1.062 1.090 1.066 1.056 1.056 1.096 1.129 1.116 1.086 1.091 6 1.135 1.175 1.155 1.121 1.128 7 1.195 1.283 1.236 1.193 1.195 8 1.276 0.963 1.333 0.969 1.287 0.967 1.261 0.968 1.272 0.967 9 1.375 0.721 1.457 0.726 1.369 0.730 1.361 0.727 1.371 0.730 2.014 2.144 1.957 1.996 2.027 11 2.076 2.255 2.041 2.029 2.066 12 2.270 2.530 2.477 2.535 2.224 2.539 2.222 2.538 2.262 2.537

Claims (9)

What is claimed is:
1. A method of preparing and analyzing granules comprising Ramulus cinnamomi extract and Poria cocos extract, the method comprises the steps of:
(a) grinding Poria cocos into fine powder to yield Poria Powder;
(b) extracting Cortex moutan by steam distillation to give a Paeonol extract and a Solid Residue I;
(c) extracting the Solid Residue I with ethanol to give Extract I, and then extracting said Solid Residue I again with hot water to give Extract TT;
(d) extracting Ramulus cinnamomi by steam distillation to give a volatile oil and a Solid Residue II;
(e) extracting the Solid Residue II with ethanol to give Extract III, and then extracting said Solid Residue II
again with hot water to give Extract TV;
(f) extracting Radix paeoniae alba, Semen persicae, and Poria cocos with ethanol to give Extract V, and then extracting said Radix paeoniae alba, Semen persicae, and Poria cocos again with hot water to give Extract VI;
(g) combining Extracts T, III and V, and removing all ethanol to give Liquid A;
(h) combining Extracts II, IV and VI, and concentrating the combined extracts to give Liquid B;
(i) combining Liquids A and B, and concentrating the liquids to give a Semisolid Extract with a relative density equal to 1.15-1.35 (60-90oC);
(j) dissolving the Paeonol extract from step (b) in ethanol, and adding the solution to an aqueous solution of beta-cyclodextrin, wherein the mixture is grinded and dried to give Inclusion Substance I;
(k) mixing the volatile oil from step (d) with beta-cyclodextrin in ethanol, wherein the mixture is grinded and dried to give Inclusion Substance II;

(1) mixing the Poria Powder from step (a) with the Semisolid Extract from step (1), wherein the mixture is dried and grinded into fine powders;
(m) mixing the fine powders from step (1) with Inclusion Substances I and II, adding ethanol to the mixture to make a dough-like mass, and passing the wet material through a sieve to obtain granules;
(n) drying said granules, and passing the dried granules through the sieve again to give final granules comprising Ramulus cinnamomi extract and Poria cocos extract; and (o) analyzing the granules by high performance liquid chromatography, thereby showing the granules contain a composition comprising a fingerprint of 12 peaks.
2. The method of claim 1, wherein the granules further comprise Paeoniflorin.
3. The method of claim 2, wherein the percentage of Paeoniflorin in the granules is 1.26-1.90%.
4. The method of claim 1, wherein the granules comprise 0.71-1.07% Paeonol.
5. The method of claim 1, wherein the granules are extracted with methanol for the high performance liquid chromatography analysis.
6. The method of claim 1, wherein Paeoniflorin is used as a standard in the high performance liquid chromatography analysis.
7. The method of claim 6, wherein the relative peak area ranges for peaks 1, 8, 9, and 12 as compared to Paeoniflorin are 0.25-0.89, 0.69-1.5, 0.3-0.85 and 1.56-3.06, respectively.
8. The method of claim 6, wherein the relative retention time ranges for peaks 1-12 as compared to Paeoniflorin are 0.209-0.314, 0.456-0.683, 0.733-0.999, 0.871-1.306, 0.921-1.382, 0.968-1.451, 1.009-1.514, 1.058-1.587, 1.152-1.728, 1.69-2.536, 1.771-2.657 and 1.943-2.915, respectively.
9. The method of claim 1, wherein the granules are formulated into a pill, capsule, tablet, suspension or syrup.
CA2659442A 2006-10-18 2007-10-17 Cinnamomi and poria composition and uses thereof Active CA2659442C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82994506P 2006-10-18 2006-10-18
US60/829,945 2006-10-18
PCT/IB2007/004483 WO2008090410A2 (en) 2006-10-18 2007-10-17 Cinnamomi and poria composition and uses thereof

Publications (2)

Publication Number Publication Date
CA2659442A1 CA2659442A1 (en) 2008-07-31
CA2659442C true CA2659442C (en) 2015-12-22

Family

ID=39644933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2659442A Active CA2659442C (en) 2006-10-18 2007-10-17 Cinnamomi and poria composition and uses thereof

Country Status (9)

Country Link
US (1) US8067040B2 (en)
EP (1) EP2073825B1 (en)
JP (1) JP5328656B2 (en)
KR (1) KR101545356B1 (en)
CN (1) CN101495129B (en)
CA (1) CA2659442C (en)
HU (1) HUE035045T2 (en)
MY (1) MY164475A (en)
WO (1) WO2008090410A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032438A1 (en) 2000-09-13 2002-04-25 Jiangsu Kanion Pharmaceutical Co. Pharmaceutical composition treating gynecological blood stasis diseases, cardio and cerebral vascular diseases, respiratory diseases and the like
US8067040B2 (en) 2006-10-18 2011-11-29 Jiangsu Kanion Pharmaceuticals, Co. Ltd. Cinnamomi and poria composition and uses thereof
JP6108452B2 (en) * 2012-04-12 2017-04-05 クラシエ製薬株式会社 Cell death inhibiting composition
CN104374839B (en) * 2014-10-31 2016-03-23 荣昌制药(淄博)有限公司 A kind of detection method for the treatment of irregular menstruation Chinese medicine composition feature
CN105194511A (en) * 2015-10-19 2015-12-30 翔宇药业股份有限公司 Medicine composition for functional uterine hemorrhage and postpartum hemorrhage
CN110870889B (en) * 2018-08-30 2022-07-29 江苏康缘药业股份有限公司 Traditional Chinese medicine composition and preparation method and application thereof
CN109632978B (en) * 2018-11-01 2021-12-21 广州科曼生物科技有限公司 Poria cocos contrast extract as well as preparation method and application thereof
CN111714568B (en) * 2019-10-24 2021-12-24 贵州益佰女子大药厂有限责任公司 Preparation method of Fuyanxiao preparation
CN113237961A (en) * 2020-11-18 2021-08-10 上海和黄药业有限公司 Method for detecting main drug effect components of cinnamon and storax in pharmaceutical preparation
CN112782326B (en) * 2020-12-30 2022-03-15 上海交通大学 Method for simultaneously measuring fingerprint spectrum and multi-index component content of Weikangling capsule
WO2023128710A1 (en) * 2021-12-30 2023-07-06 주식회사 큐라클 Tablet containing mixed extract of cinnamomi ramulus and moutan radicis cortex as active ingredient and composition designed to administer specific dosage thereof for treatment
CN115078582A (en) * 2022-06-21 2022-09-20 山东宏济堂制药集团股份有限公司 Method for determining pachymic acid A and pachymic acid B contents in Poria by one-measurement-multiple-evaluation method

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0643331B2 (en) 1985-10-04 1994-06-08 株式会社ツムラ Aldo-reductase inhibitor
JPH02255622A (en) 1989-03-28 1990-10-16 Tsumura & Co Carcinostatic assistant
JPH02255621A (en) 1989-03-29 1990-10-16 Tsumura & Co Hypotensor
GB9104286D0 (en) 1991-02-28 1991-04-17 Phytopharm Ltd Pharmaceutical compositions for the treatment of skin disorders
US5411733A (en) 1992-04-27 1995-05-02 Hozumi; Toyoharu Antiviral agent containing crude drug
CN1044683C (en) 1993-04-22 1999-08-18 陈德智 Medicine for the treatment of cough and asthma from pseudostellaria root
US5589182A (en) 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
CN1097341A (en) 1993-12-17 1995-01-18 车利群 Naomaitong hat lining
CN1113798A (en) 1994-06-18 1995-12-27 臧明礼 Chinese drug for curing gastropathy
CN1111524A (en) 1995-03-14 1995-11-15 白彦斌 Medicated wine for hypertension
JPH0930983A (en) * 1995-07-19 1997-02-04 Tsumura & Co Apoptosis inhibitor
CN1126085A (en) 1995-07-20 1996-07-10 广西中医学院 Chinese medicinal preparation for prevention and treatment of CHD and angina pectoris
CN1125613A (en) 1995-09-12 1996-07-03 王桂兰 Prescription for treatment of hysteromyoma
CN1053374C (en) 1996-02-01 2000-06-14 山东省中医药研究所 Chinese-medicinal oral liquor for curing coronary heart disease and angina pectoris and preparing method
CN1166972A (en) 1996-06-05 1997-12-10 李焕钰 Green powder medicine for discharging calculus stone
US5874084A (en) 1996-07-19 1999-02-23 Yng-Wong; Quing Non Using complex herbal formulations to treat hot flashes
CN1199618A (en) 1996-12-18 1998-11-25 虎发光 Chinese patent drug for women's diseases
US6093403A (en) 1997-08-01 2000-07-25 Phytocell Research, Inc. Sugar imbalance and diabetes treating herbal formulation
CN1060391C (en) * 1997-12-31 2001-01-10 苏新尚 Traditional Chinese medicine for treating gynecological tumour
CN1203805A (en) 1998-06-04 1999-01-06 李胤良 Health-care drink capable of preventing and curing menopathy
CN1206611A (en) 1998-06-10 1999-02-03 李树芳 Angongzhixue water taken medicine for essential uterine
CN1256947A (en) 1999-12-08 2000-06-21 杨延功 Physical constitution and food and drink health care capsule and productive method thereof
WO2002032438A1 (en) 2000-09-13 2002-04-25 Jiangsu Kanion Pharmaceutical Co. Pharmaceutical composition treating gynecological blood stasis diseases, cardio and cerebral vascular diseases, respiratory diseases and the like
JP2002193827A (en) * 2000-12-26 2002-07-10 Chugai Pharmaceut Co Ltd Chinese internal liquid medicine
US20030232102A1 (en) 2001-04-18 2003-12-18 Xinxian Zhao Total glycosides of paeony, method to prepare the same and uses thereof
CN100409866C (en) 2001-09-13 2008-08-13 江苏康缘药业股份有限公司 Chinese herbal medicine composition and preparing method
CN1241574C (en) 2002-04-10 2006-02-15 吉林天药科技股份有限公司 Medicine for relieving spasm and pain and preparation process thereof
US6916494B2 (en) 2002-10-21 2005-07-12 Chan Sik Park Anti-hemorrhoid composition and process for its manufacture
CN1651057A (en) * 2003-12-10 2005-08-10 北京市圣普华医药科技开发中心 Cinnamon poria capsule and its preparation process
CN100586425C (en) * 2003-12-10 2010-02-03 江西欧氏药业有限责任公司 Cinnamon poria capsule and its preparation process
CN1733104A (en) * 2004-08-19 2006-02-15 贵阳云岩西创药物科技开发有限公司 Cassia twig and poria cocos preparation for treating gynecopathy, its preparation and application thereof
US20060110468A1 (en) 2004-11-24 2006-05-25 Liang Liu Herbal formulations for arthritis
US7235265B2 (en) 2005-10-31 2007-06-26 Ross Rosen Herbal skin formulation
US8067040B2 (en) 2006-10-18 2011-11-29 Jiangsu Kanion Pharmaceuticals, Co. Ltd. Cinnamomi and poria composition and uses thereof

Also Published As

Publication number Publication date
JP2010506899A (en) 2010-03-04
JP5328656B2 (en) 2013-10-30
KR20090067135A (en) 2009-06-24
EP2073825A2 (en) 2009-07-01
WO2008090410A3 (en) 2008-11-13
US20100183660A1 (en) 2010-07-22
HUE035045T2 (en) 2018-05-02
MY164475A (en) 2017-12-29
US8067040B2 (en) 2011-11-29
CN101495129B (en) 2014-01-15
KR101545356B1 (en) 2015-08-18
CN101495129A (en) 2009-07-29
EP2073825A4 (en) 2013-04-17
EP2073825B1 (en) 2017-04-05
WO2008090410A4 (en) 2009-01-22
WO2008090410A2 (en) 2008-07-31
CA2659442A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
CA2659442C (en) Cinnamomi and poria composition and uses thereof
KR100558911B1 (en) Herbal Medicine Extract
CN102657823B (en) Traditional Chinese medicine composition with anticancer effect and preparation method and detection method thereof
CN102228506A (en) Composition of malaytea scurfpea extract as well as preparation method and use thereof
JP2023522297A (en) Compositions and methods for treating and preventing coronavirus infections
Dong et al. Orthogonal array design in optimizing the extraction efficiency of active constituents from roots of Panax notoginseng
CN102579734B (en) Traditional Chinese medicine composition of bone healing medicine, preparing method thereof and detecting method thereof
CN101843884B (en) Method for testing quality of antiviral oral liquid for treating hand-foot-and-mouth disease
KR20100043725A (en) Changes of protopanaxadiol ginsenosides in ginseng leaves by steaming heat treatment
CN100563662C (en) Chinese medicine active ingredient composition of treatment cardiovascular disease and preparation method thereof
JP2002538214A (en) Pharmaceutical composition for treating cardiovascular disease and method for producing the same
CN1327859C (en) Schisandra fruit extractive, its preparation process and purposes
CN117510443A (en) Lemongrass extract L01, pharmaceutical composition and application thereof
CN1879720A (en) Blood platelet-increasing tablet, its preparation process and quality control method
CN101019915A (en) Hemostatic notoginseng capsuel and its prepn process and quality control method
CN106822071B (en) Chinese medicinal effective component for treating coronary heart disease and hyperlipidemia, its preparation method and method for separating effective component from the same
CN116606269B (en) Renilla diterpenoid compound and extract L01 and application thereof in pharmacy
CN115343383B (en) Method for measuring content of 8 chemical components in adenophora root and ophiopogon root soup
CN110787201B (en) Ginseng freeze-dried orally disintegrating tablet and preparation method thereof
CN101897752B (en) Chinese medicinal composition and preparation method thereof
CN105287704A (en) Anti-cancer pharmaceutical composition and application thereof in preparation of anti-cancer medicines
Gryszczyńska et al. Comparison of phenylethanoids content in Rhodiola kirilowii and Rhodiola rosea roots applying a newly developed UPLC-MS/MS method
CN109876039A (en) Extract from the benzyl carbinol glycosides composition and preparation method thereof of bend pipe broomrape
CN113341052A (en) Method for measuring content of effective components of ephedra decoction substance standard
Oise et al. Preliminary Phytochemical and Comparative Growth Inhibitory Assay of the Aqueous and Chloroform Fractions of the Methanol Extract of The Leaves of Persea americana Mill Lauraceae

Legal Events

Date Code Title Description
EEER Examination request